The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | SYSTEMS-2: radiotherapy in mesothelioma
Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, provides insights into the SYSTEMS-2 trial which suggests that mesothelioma may be more radiosensitive than generally thought. The study aimed to determine whether administering higher doses of radiotherapy better controls pain in patients with malignant pleural mesothelioma (MPM). While the results were not statistically significant, when considering the secondary endpoint of OS, an interesting survival difference was noted. This immature data suggests that higher-dose radiotherapy treatment could affect survival outcomes. This new research avenue feeds nicely into upcoming trials such as the HIT-Meso study (NCT05655078). This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
